<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954291</url>
  </required_header>
  <id_info>
    <org_study_id>L27GRA14-1</org_study_id>
    <secondary_id>I805L27E01</secondary_id>
    <nct_id>NCT00954291</nct_id>
  </id_info>
  <brief_title>An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects</brief_title>
  <acronym>Granisetron</acronym>
  <official_title>An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to characterize the pharmacokinetic profile of granisetron&#xD;
      patch after single administration to healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to characterize the pharmacokinetic profile of granisetron&#xD;
      patch after single administration to healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t, AUC0-µ, Cmax, Tmax, T1/2, and MRT in plasma were determined with granisetron concentrations by non-compartment methods.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cancer</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Granisetron</arm_group_label>
    <description>14 mg Granisetron</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Health subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be male at the age of 20-40 years old in good health on the basis of&#xD;
             medical history, physical examination, electrocardiogram, chest X-ray, and routine&#xD;
             laboratory evaluations.&#xD;
&#xD;
          2. Vital signs (after 3 minutes resting in a upright position) which are within the&#xD;
             following ranges: Ear body temperature between 35.0-37.5 °C.Systolic blood pressure,&#xD;
             90-140 mm Hg.Diastolic blood pressure, 50-90 mm Hg.Pulse rate, 50-90 bpm.Fasting blood&#xD;
             glucose, &lt; 100 mg/dL.&#xD;
&#xD;
          3. Body weight must be above 50 kg and within -20 to +20% of ideal body weight.&#xD;
&#xD;
          4. Able to sign informed consent prior to study.&#xD;
&#xD;
          5. Able to communicate well with the investigator and comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
          2. Use of over-the-counter medications or vitamins within 14 days prior to dosing.&#xD;
&#xD;
          3. Significant illness within 2 weeks prior to dosing.&#xD;
&#xD;
          4. Participation in any clinical investigation within 2 months prior to dosing or longer&#xD;
             than required by local regulation.&#xD;
&#xD;
          5. Donate or loss more than 500 mL of blood within 3 months prior to dosing.&#xD;
&#xD;
          6. Presence of cardiovascular disease.&#xD;
&#xD;
          7. Presence of gastrointestinal disease.&#xD;
&#xD;
          8. Presence of asthma or lung disease.&#xD;
&#xD;
          9. Presence of liver disease, hepatitis B, hepatitis C or liver injury as indicated by an&#xD;
             abnormal liver function profile such as GOT, GPT, g-GT, alkaline phosphatase, serum&#xD;
             bilirubin, HBsAg, or Anti-HCV.&#xD;
&#xD;
         10. Presence of impaired renal function as indicated by abnormal creatinine or BUN values&#xD;
             or abnormal urinary constituents (e.g., albuminuria).&#xD;
&#xD;
         11. Presence of neurological disease.&#xD;
&#xD;
         12. Presence of psychiatrical disease.&#xD;
&#xD;
         13. Subject is known for HIV infected.&#xD;
&#xD;
         14. A known hypersensitivity to granisetron or its analogs.&#xD;
&#xD;
         15. History of drug or alcohol abuse within 12 months prior to dosing.&#xD;
&#xD;
         16. Permanent confinement to an institution.&#xD;
&#xD;
         17. Individuals are judged by the investigator or pharmacokineticist to be undesirable as&#xD;
             subjects for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsingjin E Liu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University - Municipal Wan Fang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsingjin E Liu, MD, PhD</last_name>
    <phone>8862-29307930</phone>
    <phone_ext>2548</phone_ext>
    <email>liuxx086@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Medical University - Municipal Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsingjin E Liu, MD, PhD</last_name>
      <phone>8862-29307930</phone>
      <phone_ext>2548</phone_ext>
      <email>liuxx086@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Hsingjin E Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>September 3, 2010</last_update_submitted>
  <last_update_submitted_qc>September 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hsingjin E. Liu, MD, PhD.</name_title>
    <organization>Taipei Medical University - Municipal Wan Fang Hospital</organization>
  </responsible_party>
  <keyword>antinauseant and antiemetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

